Chris Dougherty

Chris Dougherty is an accomplished professional with extensive experience in corporate development within the pharmaceutical industry, currently serving as Vice President and Head of Corporate Development at Jazz Pharmaceuticals since January 2012. Dougherty has led significant transactions, including the acquisition of GW Pharmaceuticals for $7 billion and other strategic license agreements totaling up to $1.7 billion. Prior roles include Senior Director and Director positions where Dougherty contributed to key acquisitions and collaborations, demonstrating a strong focus on neuroscience and oncology. Additional experience includes notable roles at Azur Pharma and Deloitte, emphasizing a solid foundation in commercial operations and audit. Dougherty holds a BS in Accounting & Finance from The Ohio State University and has served as a Board Observer at Arrivo BioVentures LLC since April 2019.